EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Intracellular delivery of full-length antibodies via organ-targeted lipid nanoparticles

Azmain Alamgir iD, Militsa Yaneva iD, Mor Sela iD, Patricia Mora-Raimundo, Haim Kadosh, Souvik Ghosal, Anas Odeh, Yuval Richtman iD, Neta Fibeesh iD, Yael Leichtmann-Bardoogo iD, Ofir Sade iD, Peleg Hasson iD und 6 weitere

Proceedings of the National Academy of Sciences · 30.06.2026 · 123 (26)

DOI: 10.1073/pnas.2531649123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 23.06.2026. Verfasst von Azmain Alamgir und 17 weiteren Autor:innen. Beteiligte Einrichtung: Robert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853. Hauptthemen laut MEDLINE: Nanoparticles, Lipids, Antibodies, Drug Delivery Systems. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cornell, Ignite Fellow for New Ventures, HHS | NIH | National Institute of General Medical Sciences (NIGMS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibodies are proteins prized for their ability to bind to extracellular antigens with exceptionally high affinities and specificities. These features have motivated researchers to utilize antibody–antigen binding to inhibit intracellular disease targets in the proteome, yet delivery of antibodies into the cytosol of cells has long been a considerable challenge. Here, we outline the development of a lipid nanoparticle (LNP) platform for delivering antibodies into cells to selectively inhibit disease-relevant cytosolic targets. This approach efficiently delivers various therapeutic antibodies into multiple cancer cell lines, inhibiting key transcription factors in inflammatory and cancer signaling pathways. We further demonstrate systemic delivery of therapeutic antibodies in disease models, including α-synuclein-specific antibodies for Parkinson’s disease and RelA-specific Immunoglobulins for acute lung injury using targeted LNP formulations. This work establishes a promising method for using LNPs for the delivery of antibody and antibody-derived therapeutics intracellularly to treat numerous proteome targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesLipidsAntibodiesDrug Delivery SystemsHumansAnimalsCell Line, TumorMiceLiposomes

Stichwörter der Autor:innen

antibody deliverylipid nanoparticlesprotein deliverytargeted delivery

Substanzen

LipidsAntibodiesLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Robert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853.
  • The Louis Family Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel.
  • Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853.
  • Department of Genetics and Developmental Biology, The Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa 32000, Israel.
  • School of Neurobiology, Biochemistry and Biophysics, George S. Wise Faculty of Life Sciences, Sagol School of Neuroscience, Tel University, Tel Aviv 6997801, Israel.
  • School of Biomedical Engineering, Engineering Faculty, Tel Aviv University, Tel Aviv 6997801, Israel.

ORCID-Profile: Azmain Alamgir, Militsa Yaneva, Mor Sela, Yuval Richtman, Neta Fibeesh, Yael Leichtmann-Bardoogo, Ofir Sade, Peleg Hasson, Rory C Chien, Uri Ashery, Ben M Maoz, Avi Schroeder, Matthew P DeLisa, Christopher A Alabi

Förderung

  • Cornell, Ignite Fellow for New Ventures
  • HHS | NIH | National Institute of General Medical Sciences (NIGMS)

Zitieren

APA

Alamgir, A., Yaneva, M., Sela, M., Mora-Raimundo, P., Kadosh, H., Ghosal, S., Odeh, A., Richtman, Y., Fibeesh, N., Leichtmann-Bardoogo, Y., Sade, O., Hasson, P., Chien, R. C., Ashery, U., Maoz, B. M., Schroeder, A., DeLisa, M. P., & Alabi, C. A. (2026). Intracellular delivery of full-length antibodies via organ-targeted lipid nanoparticles. Proceedings of the National Academy of Sciences, 123(26). https://doi.org/10.1073/pnas.2531649123

Vancouver

Alamgir A, Yaneva M, Sela M, Mora-Raimundo P, Kadosh H, Ghosal S, et al. Intracellular delivery of full-length antibodies via organ-targeted lipid nanoparticles. Proceedings of the National Academy of Sciences. 2026;123(26). doi:10.1073/pnas.2531649123

BibTeX
@article{Alamgir2026,
  author = {Alamgir, Azmain and Yaneva, Militsa and Sela, Mor and Mora-Raimundo, Patricia and Kadosh, Haim and Ghosal, Souvik and Odeh, Anas and Richtman, Yuval and Fibeesh, Neta and Leichtmann-Bardoogo, Yael and Sade, Ofir and Hasson, Peleg and Chien, Rory C and Ashery, Uri and Maoz, Ben M and Schroeder, Avi and DeLisa, Matthew P and Alabi, Christopher A},
  title = {Intracellular delivery of full-length antibodies via organ-targeted lipid nanoparticles},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {26},
  doi = {10.1073/pnas.2531649123}
}
Kostenlos starten →